ImmuPharma (LON:IMM) Shares Up 19.1% – Should You Buy?

ImmuPharma plc (LON:IMM)’s stock price was up 19.1% during mid-day trading on Friday. The stock traded as high as GBX 4.41 and last traded at GBX 4.41. 911,832 shares changed hands during mid-day trading, a decline of 63% from the average session volume of 2,481,101 shares. The stock had previously closed at GBX 3.70.

ImmuPharma Trading Up 19.1%

The firm has a market capitalization of £27.54 million, a P/E ratio of -5.31 and a beta of 3.02. The stock has a 50 day simple moving average of GBX 3.63 and a 200-day simple moving average of GBX 4.04.

ImmuPharma (LON:IMM) last issued its quarterly earnings data on Tuesday, September 15th. The company reported GBX (0.84) earnings per share for the quarter. ImmuPharma had a negative return on equity of 559.87% and a net margin of 3,519.56%. As a group, sell-side analysts expect that ImmuPharma plc will post -339.00 earnings per share for the current fiscal year.

About ImmuPharma

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.